Most Popular Choices
Share on Facebook 37 Printer Friendly Page More Sharing
Sci Tech   

Drug-resistant TB: Are we converting scientific breakthroughs into public-health gains?

By       (Page 1 of 6 pages)   No comments
Follow Me on Twitter     Message Citizen News Service - CNS
Become a Fan
  (2 fans)

BOBBY RAMAKANT - CNS

Latest episode (5th) of The Dose Podcast premiered on 2022 World TB Day worldwide
Latest episode (5th) of The Dose Podcast premiered on 2022 World TB Day worldwide
(Image by CNS)
  Details   DMCA

Undoubtedly, among the most important scientific breakthroughs for the diagnosis and treatment of drug-resistant tuberculosis (TB) have happened in the past few years. But are we able to convert the scientific breakthroughs into public-health gains quickly enough - by diagnosing every person with drug-resistant TB, and treating them with safe and effective medicines?

Science has proven that it is possible to reduce the duration of treatment of highly drug-resistant forms of TB from around 2 years to 6 months, reduce toxicity of the medicines, and significantly improve treatment outcomes. A big challenge indeed is to translate these scientific advancements into public health gains. Clock is ticking!

Know more on drug resistance

"Antimicrobial resistance, also known as drug resistance, makes an infectious agent (such as TB-causing bacteria) resistant to medicines. So, when TB bacteria becomes resistant to a medicine, then it cannot be killed by it. That is why, we need a different combination of medicines (to which bacteria is sensitive to) to treat the disease. Choice of medicines left to treat is limited, treatment is longer, risk of severe illness and dying is higher, and host of issues such as, drug toxicity, side effects, and sometimes post-treatment disabilities, are other challenges. But there is good news too - thanks to rigorous scientific research, we have shorter, safer, and more effective therapies for treating drug-resistant TB now. We need to ensure that standard and best possible treatment options reach everyone in need without any delay. No excuse for inaction," said Shobha Shukla, founder Executive Director of CNS who was moderating The Dose Podcast.

The Dose Podcast

The latest episode of The Dose Podcast, which premiered on 2022 World TB Day (launched by the Working Group of New TB Drugs of Stop TB Partnership), featured two TB science leaders who have been instrumental in advancing scientific research for highly drug-resistant TB.

"Highly drug-resistant TB as it was referred to in the Nix-TB and ZeNix scientific studies, was the combination of either XDR-TB or pre-XDR-TB (using the pre-2021 definitions) or MDR-TB with treatment intolerance or non-responsive MDR-TB," said Dr Gustavo Velasquez, Assistant Professor in the Division of HIV Infectious Diseases and Global Medicine at University of California.

Next Page  1  |  2  |  3  |  4  |  5  |  6

(Note: You can view every article as one long page if you sign up as an Advocate Member, or higher).

Rate It | View Ratings

Citizen News Service - CNS Social Media Pages: Facebook page url on login Profile not filled in       Twitter page url on login Profile not filled in       Linkedin page url on login Profile not filled in       Instagram page url on login Profile not filled in

Citizen News Service (CNS) specializes in in-depth and rights-based, health and science journalism. For more information, please contact: www.citizen-news.org or @cns_health or www.facebook.com/cns.page
Go To Commenting
The views expressed herein are the sole responsibility of the author and do not necessarily reflect those of this website or its editors.
Writers Guidelines

 
Contact AuthorContact Author Contact EditorContact Editor Author PageView Authors' Articles
Support OpEdNews

OpEdNews depends upon can't survive without your help.

If you value this article and the work of OpEdNews, please either Donate or Purchase a premium membership.

STAY IN THE KNOW
If you've enjoyed this, sign up for our daily or weekly newsletter to get lots of great progressive content.
Daily Weekly     OpEd News Newsletter
Name
Email
   (Opens new browser window)
 

Most Popular Articles by this Author:     (View All Most Popular Articles by this Author)

Management of respiratory diseases beyond drugs: Pulmonary Rehabilitation

Oxygen therapy is like a prescription drug: Use it rationally

New funding boosts research for controlling TB, malaria, dengue and leishmaniasis

Progress made but work remains on firewalling health policy from tobacco industry

Youth Changemakers at the forefront of advocating for sexual health and rights

A bouquet of novel compounds: New treatment options for HIV

To View Comments or Join the Conversation:

Tell A Friend